These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 35361141)

  • 21. Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir.
    Suzuki F; Sezaki H; Akuta N; Suzuki Y; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Suzuki Y; Kumada H
    Drug Des Devel Ther; 2014; 8():869-73. PubMed ID: 25061278
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures.
    Kim YJ; Sinn DH; Gwak GY; Choi MS; Koh KC; Paik SW; Yoo BC; Lee JH
    World J Gastroenterol; 2012 Dec; 18(47):6996-7002. PubMed ID: 23322999
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study.
    Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Kim K; Kitrinos KM; Subramanian GM; McHutchison JG; Yee LJ; Elkhashab M; Berg T; Sporea I; Yurdaydin C; Husa P; Jablkowski MS; Gane E
    J Hepatol; 2017 Jan; 66(1):11-18. PubMed ID: 27545497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B.
    Park CH; Jung SW; Shin JW; Bae MA; Lee YI; Park YT; Chung HS; Park NH
    Clin Mol Hepatol; 2016 Mar; 22(1):152-9. PubMed ID: 27044766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiviral Efficacy of Tenofovir Monotherapy in Children with Nucleos(t)ide-naive Chronic Hepatitis B.
    Choe JY; Ko JS; Choe BH; Kim JE; Kang B; Lee KJ; Yang HR
    J Korean Med Sci; 2018 Jan; 33(2):e11. PubMed ID: 29215820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tenofovir
    Rodríguez M; Pascasio JM; Fraga E; Fuentes J; Prieto M; Sánchez-Antolín G; Calleja JL; Molina E; García-Buey ML; Blanco MÁ; Salmerón J; Bonet ML; Pons JA; González JM; Casado MÁ; Jorquera F;
    World J Gastroenterol; 2017 Nov; 23(41):7459-7469. PubMed ID: 29151700
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of virologic response to tenofovir mono-rescue therapy for multidrug resistant chronic hepatitis B.
    Lee S; Park JY; Kim D Y; Kim BK; Kim SU; Song K; Ku HJ; Han KH; Ahn SH
    J Med Virol; 2016 Jun; 88(6):1027-34. PubMed ID: 26538234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response.
    Woo HY; Park JY; Bae SH; Kim CW; Jang JY; Tak WY; Kim DJ; Kim IH; Heo J; Ahn SH
    Clin Mol Hepatol; 2020 Jul; 26(3):352-363. PubMed ID: 32460460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons.
    Bihl F; Martinetti G; Wandeler G; Weber R; Ledergeber B; Calmy A; Battegay M; Cavassini M; Vernazza P; Caminada AP; Rickenbach M; Bernasconi E;
    BMC Gastroenterol; 2015 Jul; 15():79. PubMed ID: 26152237
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative evaluation of long-term monotherapies & combination therapies in patients with chronic hepatitis B: A pilot study.
    Srivastava M; Singh N; Dixit VK; Nath G; Jain AK
    Indian J Med Res; 2016 Sep; 144(3):424-432. PubMed ID: 28139541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Switching from tenofovir and nucleoside analogue therapy to tenofovir monotherapy in virologically suppressed chronic hepatitis B patients with antiviral resistance.
    Kim DY; Lee HW; Song JE; Kim BK; Kim SU; Kim DY; Ahn SH; Han KH; Park JY
    J Med Virol; 2018 Mar; 90(3):497-502. PubMed ID: 29077211
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence of tenofovir resistance in chronic hepatitis B virus (HBV) infection: An observational case series of South African adults.
    Mokaya J; Maponga TG; McNaughton AL; Van Schalkwyk M; Hugo S; Singer JB; Sreenu VB; Bonsall D; de Cesare M; Andersson M; Gabriel S; Taljaard J; Barnes E; Preiser W; Van Rensburg C; Matthews PC
    J Clin Virol; 2020 Aug; 129():104548. PubMed ID: 32663786
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of entecavir-based rescue therapy in lamivudine-resistant chronic hepatitis B patients in China: a retrospective study.
    Li W; Wang L; Liu Y; Li Y; Yu S
    Pharmazie; 2018 Apr; 73(4):223-247. PubMed ID: 29609690
    [TBL] [Abstract][Full Text] [Related]  

  • 34. No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment.
    Liu Y; Corsa AC; Buti M; Cathcart AL; Flaherty JF; Miller MD; Kitrinos KM; Marcellin P; Gane EJ
    J Viral Hepat; 2017 Jan; 24(1):68-74. PubMed ID: 27658343
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.
    Berg T; Marcellin P; Zoulim F; Moller B; Trinh H; Chan S; Suarez E; Lavocat F; Snow-Lampart A; Frederick D; Sorbel J; Borroto-Esoda K; Oldach D; Rousseau F
    Gastroenterology; 2010 Oct; 139(4):1207-17. PubMed ID: 20600025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure.
    Zoulim F; Białkowska-Warzecha J; Diculescu MM; Goldis AE; Heyne R; Mach T; Marcellin P; Petersen J; Simon K; Bendahmane S; Klauck I; Wasiak W; Janssen HL
    Hepatol Int; 2016 Sep; 10(5):779-88. PubMed ID: 27206517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Core promoter mutant HBV non-responding to adefovir after viral breakthrough on lamivudine: rapid virologic response to tenofovir plus lamivudine in a cirrhotic patient.
    Katsounas A; Jochum C; Canbay A; Schlaak J; Gerlich WH; Gerken G
    Eur J Med Res; 2008 Oct; 13(10):472-5. PubMed ID: 19008175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of tenofovir disoproxil fumarate resistance after complete viral suppression in a patient with treatment-naïve chronic hepatitis B: A case report and review of the literature.
    Cho WH; Lee HJ; Bang KB; Kim SB; Song IH
    World J Gastroenterol; 2018 May; 24(17):1919-1924. PubMed ID: 29740207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients.
    Kim HJ; Cho JY; Kim YJ; Gwak GY; Paik YH; Choi MS; Koh KC; Paik SW; Yoo BC; Lee JH
    Korean J Intern Med; 2015 Jan; 30(1):32-41. PubMed ID: 25589833
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes.
    Mello FC; Fernandes CA; Gomes Sde A
    Mem Inst Oswaldo Cruz; 2012 May; 107(3):317-25. PubMed ID: 22510826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.